Rigel, Bristol-Myers Squibb Partner to Develop Cancer Immunotherapies
Sunday, March 1, 2015
Source: Pharmaceutical Business Review
Rigel Pharmaceuticals and Bristol-Myers Squibb have partnered for the discovery, development and commercialization of cancer immunotherapies.
The cancer immunotherapies will be developed and commercialized by using Rigel's small molecule TGF beta receptor kinase inhibitors range.
Through the partnership, Bristol-Myers Squibb will secure exclusive, global rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer.
Rigel Pharmaceuticals president and CEO Raul Rodriguez said: "This collaboration places our TGF beta receptor kinase inhibitor program into the hands of Bristol-Myers Squibb, a premier immuno-oncology company. Together, we believe TGF beta inhibition may offer novel therapeutic opportunities in oncology treatments.